Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00006495
Status:
COMPLETED
Last Update Posted:
2021-11-01
First Post:
2000-11-15
Brief Title:
Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
Augmentation of HIV-Specific Helper and CTL Responses Through Therapeutic Vaccination in Individuals Receiving Potent Suppressive Antiretroviral Therapies
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see how the vaccines Remune HIV-1 immunogen and vCP1452 affect immune responses in patients who also are taking anti-HIV medications This study also will see if these vaccines are safe to use either alone or in combination
Treatment with anti-HIV drugs does not always keep HIV viral load low and under control This study will look at the effect of the HIV vaccine vCP1452 on the immune response and how it works in combination with Remune Information about immune responses and the safety of these vaccines in HIV-positive patients will be gathered
Treatment with anti-HIV drugs does not always keep HIV viral load low and under control This study will look at the effect of the HIV vaccine vCP1452 on the immune response and how it works in combination with Remune Information about immune responses and the safety of these vaccines in HIV-positive patients will be gathered
Detailed Description:
Human viral infections are controlled by the immune system However the multiple immune responses provoked by HIV infection do not control the infection in most people The ability to specifically augment CTL responses with an immunotherapeutic vaccine may strengthen the containment of viremia afforded by antiretroviral agents and thereby extend the durability of viral suppression The current study will attempt to determine whether therapeutic immunizations with HIV-1 immunogen and vCP1452 are safe and able to augment HIV-1 specific immune responses for a longer period of time than antiretroviral therapy alone and if both agents are better than either by itself
Patients currently enrolled in A5058s under A5057A5058s Versions 10 and 20 will be given the option of continuing their participation in A5058s through this independent study Rollover patients register to Step II and begin treatmentevaluations on A5058s at the same study week that they were on in Versions 10 and 20 of A5057A5058s New patients enter Step I and will not need to register to Step II Step I patients are stratified on the basis of HIV viral load antiretroviral history and current antiretroviral treatment Within each stratum patients are randomized to 1 of the following 4 treatment arms HIV-1 immunogen plus ALVAC placebo HIV-1 immunogen placebo plus ALVAC placebo HIV-1 immunogen placebo plus vCP1452 or HIV-1 immunogen plus vCP1452 Patients receive an injection at study entry and every 12 weeks thereafter until the end of the study a minimum of 2 years Step II patients receive the same treatment as patients in Step I Patients are evaluated every 12 weeks for clinical immunologic and virologic parameters Patients continue taking the antiretroviral treatment that they were taking at study entry until reaching a virologic relapse as defined in the protocol If no response to a new drug regimen occurs or the antiretroviral therapy is not changed immunizations may continue as long as the viral load remains below 5000 copiesml
Patients currently enrolled in A5058s under A5057A5058s Versions 10 and 20 will be given the option of continuing their participation in A5058s through this independent study Rollover patients register to Step II and begin treatmentevaluations on A5058s at the same study week that they were on in Versions 10 and 20 of A5057A5058s New patients enter Step I and will not need to register to Step II Step I patients are stratified on the basis of HIV viral load antiretroviral history and current antiretroviral treatment Within each stratum patients are randomized to 1 of the following 4 treatment arms HIV-1 immunogen plus ALVAC placebo HIV-1 immunogen placebo plus ALVAC placebo HIV-1 immunogen placebo plus vCP1452 or HIV-1 immunogen plus vCP1452 Patients receive an injection at study entry and every 12 weeks thereafter until the end of the study a minimum of 2 years Step II patients receive the same treatment as patients in Step I Patients are evaluated every 12 weeks for clinical immunologic and virologic parameters Patients continue taking the antiretroviral treatment that they were taking at study entry until reaching a virologic relapse as defined in the protocol If no response to a new drug regimen occurs or the antiretroviral therapy is not changed immunizations may continue as long as the viral load remains below 5000 copiesml
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AACTG A5058s | Registry Identifier | DAIDS ES Registry Number | None |
| 10674 | REGISTRY | None | None |
| ACTG A5058s | None | None | None |